ABC | Volume 112, Nº3, March 2019

Updated The Brazilian Society of Cardiology and Brazilian Society of Exercise and Sports Medicine Updated Guidelines for Sports and Exercise Cardiology - 2019 Arq Bras Cardiol. 2019; 112(3):326-368 179. Aziz PF, Sweeten T, Vogel RL, Bonney WJ, Henderson J, Patel AR, et al. Sports participation in genotype positive childrenwith longQT syndrome. JACC Clin Electrophysiol. 2015;1(1-2):62-70. 180. AckermanMJ,ZipesDP,KovacsRJ,MaronBJ.Eligibilityanddisqualification recommendations for competitive athletes with cardiovascular abnormalities: task force 10: the cardiac channelopathies: a scientific statement from the American Heart Association and American College of Cardiology. J Am Coll Cardiol. 2015;66(21):2424-8. 181. Steinberg C. Diagnosis and clinical management of long-QT syndrome. Curr Opin Cardiol. 2018;33(1):31-41. 182. Ahn J, KimHJ, Choi JI, Lee KN, Shim J, AhnHS, et al. Effectiveness of beta- blockers depending on the genotype of congenital long-QT syndrome: a meta-analysis. PLoS One. 2017;12(10):e0185680. 183. Pérez-Riera AR, Barbosa-Barros R, Daminello Raimundo R, da Costa de Rezende Barbosa MP, Esposito Sorpreso IC, de Abreu LC. The congenital long QT syndrome Type 3: an update. Indian Pacing Electrophysiol J. 2018;18(1):25-35. 184. Shah SR, Park K. Long QT syndrome: a comprehensive review of the literature and current evidence. Curr Probl Cardiol. 2018 May 10. pii: S0146-2806(18)30051-3. 185. Bjerregaard P. Diagnosis and management of short QT syndrome. Heart Rhythm. 2018;15(8):1261-7. 186. Sharma S, Drezner JA, Baggish A, Papadakis M,WilsonMG, Prutkin JM, et al. International recommendations for electrocardiographic interpretation in athletes. J Am Coll Cardiol. 2017;69(8):1057-75. 187. Cubeddu LX. Drug-induced inhibition and trafficking disruption of ion channels: pathogenesis of QT abnormalities and drug-induced fatal arrhythmias. Curr Cardiol Rev. 2016;12(2):141-54. 188. El-Battrawy I, LanH, Cyganek L, Zhao Z, Li X, Buljubasic F, et al. Modeling short QT syndrome using human-induced pluripotent stem cell-derived cardiomyocytes. J AmHeart Assoc. 2018;7(7). pii: e007394. 189. Gaita F, Giustetto C, Bianchi F, Schimpf R, Haissaguerre M, Calò L, et al. Short QT syndrome: pharmacological treatment. J Am Coll Cardiol. 2004;43(8):1494-9. 190. Mondoly P, Cardin C, Rollin A, Duparc A, Maury P. Use of a subcutaneous ICD in a patient with short QT syndrome. Clin Case Rep. 2015;4(1):35-8. 191. Schimpf R, Wolpert C, Bianchi F, Giustetto C, Gaita F, Bauersfeld U, et al. Congenital short QT syndrome and implantable cardioverter defibrillator treatment: inherent risk for inappropriate shock delivery. J Cardiovasc Electrophysiol. 2003;14(12):1273-7. 192. Gourraud JB, Barc J, Thollet A, Le Marec H, Probst V. Brugada syndrome: diagnosis, risk stratification and management. Arch Cardiovasc Dis. 2017;110(3):188-95. 193. Argenziano M, Antzelevitch C. Recent advances in the treatment of Brugada syndrome. Expert Rev Cardiovasc Ther. 2018;16(6):387-404. 194. Antzelevitch C, Yan GX, Ackerman MJ, Borggrefe M, Corrado D, Guo J, et al. J-Wave syndromes expert consensus conference report: emerging concepts and gaps in knowledge. Europace. 2017;19(4):665-694. 195. Ghouse J, Have CT, Skov MW, Andreasen L, Ahlberg G, Nielsen JB, et al. Numerous Brugada syndrome-associated genetic variants have no effect on J-point elevation, syncope susceptibility, malignant cardiac arrhythmia, and all-cause mortality. Genet Med. 2017;19(5):521-8. 196. Gray B, Hasdemir C, Ingles J, Aiba T, Makita N, Probst V, et al. Lack of genotype-phenotype correlation in Brugada syndrome and sudden arrhythmic death syndrome families with reported pathogenic SCN1B variants. Heart Rhythm. 2018;15(7):1051-1057. 197. WuW, Tian L, Ke J, Sun Y, Wu R, Zhu J, et al. Risk factors for cardiac events in patients with Brugada syndrome: a PRISMA-compliant meta-analysis and systematic review. Medicine (Baltimore). 2016;95(30):e4214. 198. Antzelevitch C, Brugada P, Borggrefe M, Brugada J, Brugada R, Corrado D, et al. Brugada syndrome: report of the second consensus conference. Heart Rhythm. 2005;2(4):429-40. 199. Pérez-Riera AR, Barbosa-Barros R, de Rezende Barbosa MP, Daminello- RaimundoR,deLuccaAAJr,deAbreuLC.Catecholaminergicpolymorphic ventricular tachycardia, an update. Ann Noninvasive Electrocardiol. 2018;23(4):e12512. 200. Kannankeril PJ, Moore JP, Cerrone M, Priori SG, Kertesz NJ, Ro PS, et al. Efficacy of flecainide in the treatment of catecholaminergic polymorphic ventricular tachycardia: a randomized clinical trial. JAMA Cardiol. 2017;2(7):759-66. 201. Li N, Wang Q, Sibrian-Vazquez M, Klipp RC, Reynolds JO, Word TA, et al. Treatment of catecholaminergic polymorphic ventricular tachycardia in mice using novel RyR2-modifying drugs. Int J Cardiol. 2017 Jan 15;227:668-73. 202. SumitomoN. Current topics in catecholaminergic polymorphic ventricular tachycardia. J Arrhythm. 2016;32(5):344-51. 203. Wall JJ, Iyer RV. Catecholaminergic polymorphic ventricular tachycardia. Pediatr Emerg Care. 2017;33(6):427-431. 204. Roston TM, Vinocur JM, Maginot KR, Mohammed S, Salerno JC, Etheridge SP, et al. Catecholaminergic polymorphic ventricular tachycardia in children: analysis of therapeutic strategies and outcomes from an international multicenter registry. Circ Arrhythm Electrophysiol. 2015;8(3):633-42. 205. PrioriSG,NapolitanoC,MemmiM,ColombiB,DragoF,GaspariniM,etal. Clinical andmolecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia. Circulation. 2002;106(1):69-74. 206. Imberti JF, Underwood K, Mazzanti A, Priori SG. Clinical challenges in catecholaminergic polymorphic ventricular tachycardia. Heart Lung Circ. 2016;25(8):777-83. 207. Liu N, Ruan Y, Priori SG. Catecholaminergic polymorphic ventricular tachycardia. Prog Cardiovasc Dis. 2008;51(1):23-30. 208. Xiong J, Liu X, Gong Y, Zhang P, Qiang S, Zhao Q, et al. Pathogenic mechanism of a catecholaminergic polymorphic ventricular tachycardia causing-mutation in cardiac calcium release channel RyR2. J Mol Cell Cardiol. 2018 Apr;117:26-35. 209. Ackerman MJ, Priori SG, Dubin AM, Kowey P, Linker NJ, Slotwiner D, et al. Beta-blocker therapy for long QT syndrome and catecholaminergic polymorphic ventricular tachycardia: Are all beta-blockers equivalent? Heart Rhythm. 2017;14(1):e41-e44. 210. Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP 3rd, Guyton RA, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on PracticeGuidelines. J AmColl Cardiol. 2014;63(22):2438-88. Erratum in: J Am Coll Cardiol. 2014;63(22):2489. 211. Siu SC, Silversides CK. Bicuspid aortic valve disease. J Am Coll Cardiol. 2010;55(25):2789-800. 212. Taniguchi T, Morimoto T, Shiomi H, Ando K, Kanamori N, Murata K, et al; CURRENT AS Registry Investigators. Sudden death in patients with severe aortic stenosis: observations from the CURRENT AS registry. J Am Heart Assoc. 2018;7(11). pii: e008397. 213. Kanwar A, Thaden JJ, Nkomo VT. Management of patients with aortic valve stenosis. Mayo Clin Proc. 2018;93(4):488-508. 214. Maron BJ. Sudden death in young athletes. N Engl J Med. 2003;349(11):1064-75. 215. Tarasoutchi F, MonteraMW, Ramos AI, Sampaio RO, Rosa VE, Accorsi TA, et al.AtualizaçãodasDiretrizesBrasileirasdeValvopatias:AbordagemdasLesões Anatomicamente Importantes. Arq Bras Cardiol. 2017;109(6 Supl. 2):1-34. 216. Baumgartner H, Otto CM. Aortic stenosis severity: do we need a new concept? J Am Coll Cardiol. 2009;54(11):1012-3. 217. Mantini C, Di Giammarco G, Pizzicannella J, Gallina S, Ricci F, D'Ugo E, et al.Gradingofaorticstenosisseverity:ahead-to-headcomparisonbetween cardiacmagnetic resonance imaging and echocardiography. Radiol Med. 2018;123(9):643-54. 363